An evidence-based approach to the management of pulmonaryarterial hypertensionStephen L. and Evangelos D. Michelakis Purpose of review Sponsorship: S.L.A. is supported by NIH-RO1-HL071115. Both authors are Evidence-based therapies and guidelines for pulmonary supported by the Canada Foundation for Innovation, the Alberta Heart and StrokeFoundation, the Canadian Institutes for Health Research (CIHR) and the Alberta
Market outlook 29th june 09Market Outlook 17th Nov, 2015
NIFTY HELDS ITS SUPPORT OF 7750-7800; THANKS TO IMPRESSIVE GAINS IN BANK NIFTY; AVOID TRADING
THE NIFTY INDEX AND FOCUS ON BLUE CHIPS; LONG POSITIONS SHOULD BE PROTECTED IN BANK NIFTY
WITH A TRAILING STOP LOSS.
It was a trend day in the Bank Nifty where prices opened with a gap down of 70 points at 17681 and went further lower to register a low of 16855.50. However, prices seen a stupendous rally of nearly 380 points from this low within couple of hours. Finally index closed near the highs at 17170.45 with a gain of nearly 220 points. On Friday, we told our readers about the narrow range in which bank Nifty was trading from last three trading sessions and a big move in the index was imminent. Therefore, we had suggested buying the bank nifty above 17069 or selling below 16590. The prices have seen a big range day and went above 17069; hence we have taken a long position there. Now traders should hold on to this long position with a revised stop loss of 16930. CNX IT opened with a gap down. The index made its day low below 11000 at 10940. Price bounced back from that low and closed above 11000 with a loss of 67 points. The index traded in a large range of nearly 151 points. It was the 4th consecutive lower closing day in CNX IT. Also the index has seen a decline of almost 750 points in last 7 trading days. After such a big decline price tend to trade choppy and range bound. A support comes at 10950 – 11000 zones. We may see some choppy price action here. Avoid this sector for any king of buying. A close above 11300 will be the first sign for an uptrend. Intermediate trend is sideways whereas short term trend is now up in MEDIA Sector. Prices have seen a correction and find support. We may see an upside rally here. DISH TV and ZEEL had seen a decline and then prices hold its support in these two stocks. Look for a buying opportunity here. SUN TV and TV18BRDCST were trading narrow and saw a breakout from trading ranges. Look for buying in these two stocks. DESCRIPTION
Intermediate trend is sideways in ASIANPAINT. The stock has seen a decline and then finds support near 785. Prices are holding this support so far and trading very narrow. We may see an upside rally here. Buy this stock above 804. If this trade executes then place your stop just below 794 and a target near 825. Intermediate Trend is sideways in COALINDIA. The stock is consolidating at its bottom after a big decline. Prices are making a pattern of bullish Head & Shoulder. We may see an upside rally here. Buy this stock above 332. If this trade executes then place your stop just below 325 and a target near 346. Intermediate trend is down in INFRATEL. The stock has been trading inside a range from last seven trading days. Prices are now at the verge of breakdown from this range. Sell this stock below 365. If this trade executes then place your stop just above 372 and a target near 351. Intermediate Trend is up in ORIENTBANK. The stock has seen an upside move today and broken above to its resistance near 150. We may see higher level in this stock. Buy this stock above 153. If this trade executes then place your stop just below 149 and a target near 161.
FIIs net Sell 6.46 Bln rupees shares in Index Future FIIs net Sell 3.58 Bln rupees shares in Stock Future FIIs provisionally net Sell 10.51 Bln rupees shares DIIs provisionally net Buy 6.62 Bln rupees shares
ICICI Bank Ltd will sell part stake in its life insurance venture to Premji Invest and a company owned by Temasek Holdings of Singapore valuing the company at Rs. 32,500 crores, nearly Rs. 5,000 crores lower than what it did when it sold stock options to staff last year. Ajanta Pharma Ltd has launched generic version of Singulair granules, used in the treatment of asthma, in Arogya Finance has tied up with Dr Reddy's Laboratories for providing medical loans for treatment of Talwalkars Better Value Fitness (TBVF) has picked up a majority stake in Chennai-based firm Inshape Health and Fitnez. Reliance infrastructure had agreed to sell 49 percent of its Mumbai power operations to Canada's Public Sector Pension Investment Board. Inox Wind is commissioning a 800 MW facility at its manufacturing unit in Madhya Pradesh to double production capacity to 1,600 MW. Source:Economic Times, Business Standard
Quarterly Results Quarterly Results Quarterly Results Quarterly Results Quarterly Results
Interim Dividend - Rs. - 6.0000 Interim Dividend - Rs. - 1.8000 Interim Dividend - Rs. - 6.0000 Interim Dividend - Rs. - 0.1000 Interim Dividend - Rs. - 0.4500 Interim Dividend - Rs. - 3.0000 Interim Dividend - Rs. - 2.2500 Interim Dividend - Rs. - 15.0000 Interim Dividend - Rs. - 0.6000 Interim Dividend - Rs. - 1.0000 Interim Dividend - Rs. - 21.0000 Interim Dividend - Rs. - 2.5000 Interim Dividend - Rs. - 2.5000 Interim Dividend - Rs. - 3.0000 Interim Dividend - Rs. - 1.2000 Interim Dividend - Rs. - 1.0000 Interim Dividend - Rs. - 1.0000 Interim Dividend - Rs. - 4.0000 Interim Dividend - Rs. - 3.0000 Interim Dividend - Rs. - 0.4000 Interim Dividend - Rs. - 2.5000 Interim Dividend - Rs. - 1.5000 Interim Dividend - Rs. - 1.2000 Interim Dividend - Rs. - 1.0000 Interim Dividend - Rs. - 0.3000 Interim Dividend - Rs. - 0.6000 Stock Split From Rs.5/- to Rs.1/- Interim Dividend - Rs. - 5.0000 Stock Split From Rs.10/- to Rs.2/- Interim Dividend - Rs. - 0.9000 Buy Back of Shares Consolidation of Shares Interim Dividend - Rs. - 8.5000 Stock Split From Rs.10/- to Rs.1/- Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014
Elite Wealth Advisors Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Advisors
Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making
their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go tAnalysts employed by Elite Wealth Advisors
Limited are registered/qualified (applied for) as research analysts with SEBI in India.
Analyst Certification (For Reports)
C SrinivasaKalyan, MBA, M.Com (F&C), MA (Eco), Elite Wealth Advisors Limited
IsrailKhan,Bcom,Elite Wealth Advisors Limited
Raushan Kumar, MBA, Elite Wealth Advisors Limited, [email protected]
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or
their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views
expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Advisors Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer
that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views
expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures,
investment thesis, valuation methodology, and risks to rating and price targets, please visi
Important disclosures, including price charts, are available and all Elite Wealth Advisors Limited covered companies by visitingor e-
mailing [email protected] with your request. Elite Wealth Advisors Limited may screen companies based on Strategy, Technical, and Quantitative
Research. For important disclosures for these companies, please e-mail [email protected]
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk
disclosure documents. For a copy of the risk disclosure documents, please contact your Broker's Representative or visit the OCC's website at
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made
available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker's sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Advisors Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst's area of
coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Advisors Limited. Analyst as officer or director: Elite Wealth
Advisors Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, advisory board member or employee of any
company in the analyst's area of coverage.
Country Specific Disclosures
India - For private circulation only, not for sale.
Legal Entities Disclosures
Mr. RavinderParkash Seth is the Managing Director of Elite Wealth Advisors Ltd (EWAL, henceforth), having its registered office at S-110, Sahara Mall, M.G. Road,
Gurgaon (Corporate Office-S-8, DDA Shopping Complex, MayurVihar Phase-1, New Delhi-110091), is a SEBI registered Research Analyst (SEBI Registration Number-
applied for) and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWAL Advisory discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers
research report, details of associates and such other information as is necessary to take an investment decision, including the following:
a) EWAL Advisory or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWAL Advisory or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end
of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWAL Advisory or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public
(a) EWAL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWAL Advisory or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWAL Advisory or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject
company in the past twelve months;
(d) EWAL Advisory or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage
services from the subject company in the past twelve months;
(e) EWAL Advisory or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research
3 In respect of Public Appearances
(a) EWAL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services
provided by EWAL Advisory
Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and
(b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant
banking or brokerage services transactions of the subject company.
(4) EWAL Advisory or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWAL Advisory has never been engaged in market making activity for the subject company;
(6) EWAL Advisory shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.
Join a Breakthrough canine clinical trial of Immunotherapy Using serial C-reaCtive Protein (CrP) MeasUreMents in Dogs information Guide immune system Patterns - emerging evidence evidence gathered over the past few years agent, killing t-regulatory cells at the time of has made it clear that the immune system is division and thus allowing the t-effectors cells to